Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study.

ABSTRACT:

Background

New pharmacological treatment strategies are urgently needed for schizophrenia since current antipsychotic medications have limitations related to efficacy, tolerability, and disease course modification. Different lines of evidence converge on aberrant activity of the immune system, but translation into new treatment is still pending. Studies investigating the antipsychotic properties of less potent anti-inflammatory drugs have provided equivocal findings. A potent agent like prednisolone might be better suited for establishing proof-of-concept that dampening of inflammation may be beneficial in schizophrenia.

Methods

In this double-blind multicentre pilot study, 12 patients (aged 18-39) with schizophrenia maintained on stable antipsychotic regimens were randomize

SUBMITTER: Hoprekstad GE 

PROVIDER: S-EPMC12302662 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature